Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DRUG LEGISLATIVE ACTIVITY WILL CENTER LARGELY IN SENATE

Executive Summary

DRUG LEGISLATIVE ACTIVITY WILL CENTER LARGELY IN SENATE Labor & Human Resources Committee during the 101st Congress. Chairman Kennedy (D-Mass.) is reportedly planning hearings on the Orphan Drug Act and the high cost to patients for drugs like human growth hormone and AZT. Kennedy and the committee's Ranking Minority Member Hatch (Utah) will also be spearheading efforts toward FDA "revitalization." Plans are likely to include broader hearings to review the FD&C Act. In addition to seeking increased funding for centralized facilities and more personnel, such hearings could examine the drug approval process, particularly for drugs for AIDS and other life-threatening diseases. The Senate committee will be taking the lead on many drug-related proposals, which in the past have been subject of greater activity in the House. This year Rep. Waxman's (D-Calif.) Health Subcommittee will spend less time on drug issues while focusing on other areas, such as food labeling. Another primary item on Waxman's agenda will be medical device amendments. The California Democrat, however, will continue to monitor such drug issues as pricing, advertising, and implementation of the Catastrophic Care and the animal drug laws passed last year. The orphan drug issue is an example. In the 100th Congress, Waxman held hearings and markups on legislation he sponsored to amend the Orphan Drug Law. His primary interest was the market exclusivity benefit which he wanted to be shared by more than one company in certain instances. FDA and the National Organization for Rare Diseases testified in favor of an amendment that would permit subsequent orphan drug developers to share a prime developer's exclusivity if the later products had reached a certain stage (for example, Phase III clinicals or NDA submission) by the time the first product was approved. FDA Commissioner Young referred to these situations as "inadvertant, coincidental" orphan drug development. As recently as a matter of weeks ago, the HHS National Commission on Orphan Diseases was considering a recommendation for shared exclusivity. However, none of these groups now endorses the concept of shared exclusivity, citing fears that it may discourage orphan drug development. Consequently, finding there is no readily apparent "legislative fix" for the high prices and other concerns associated with market exclusivity, Waxman is simply monitoring the situation. Greater demand for amendments may surface after approval of erythropoietin, another orphan drug with a potentially large market. Kennedy's interest, on the other hand, is growing. His constituents now include drug research firms who are locked out of the human growth hormone market by the Orphan Drug Act's exclusivity provisions. The heavy concentration of the biotech industry in Massachusetts, along with a new committee staff, have changed Kennedy's profile since the late 1970s, the last time he held hearings involving the drug industry.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel